tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TNF Pharmaceuticals Discusses Isomyosamine Progress in Call

Story Highlights
TNF Pharmaceuticals Discusses Isomyosamine Progress in Call

Elevate Your Investing Strategy:

An update from TNF Pharmaceuticals ( (TNFA) ) is now available.

On March 6, 2025, TNF Pharmaceuticals held a telephonic conference call to discuss the progress of their lead compound, Isomyosamine. The company provided updates on their research and development efforts, but emphasized that the information shared is not necessarily material or required to be disclosed under regulatory obligations.

More about TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the research and development of medical compounds, with a primary emphasis on their lead compound, Isomyosamine.

YTD Price Performance: -67.83%

Average Trading Volume: 537,931

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $1.02M

Find detailed analytics on TNFA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1